Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dance 501 PK/PD in Asthma/COPD
NCT03307512Phase 2Terminated
- Sponsor
- Aerami Therapeutics
- Start
- Feb 2018
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Dance-501 in diabetes mellitus (DM) (2 arms), sponsored by Aerami Therapeutics. Primary endpoints: Area under the insulin curve at 10 hours and Area under the glucose infusion rate curve at 10 hours. Started Feb 2018; status: terminated.
02
Drugs
Dance-501
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03307512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03307512.